Recently, our team attended the 2018 Inland Empire Stem Cell Consortium hosted by Western University of Health Sciences in Pomona.  The IESCC is comprised of stem cell researchers located throughout the Inland Empire from four universities, including University of California-Riverside, Western University of Health Sciences, Loma Linda University, and California State University-San Bernardino.

While still a relatively new annual event featuring  stem cell researchers and scientists, the event has grown considerably.  IESCC serves as a great venue for professors and students from local universities to present their work to an enthusiastic audience. The two keynotes were excellent talks focused on human cell therapy. The speakers, Dr. Christine Brown from City of Hope and Dr. Song Li from UCLA, set the stage for a series of thought-provoking discussions. Many of the posters were also focused on specific technical aspects of cell therapy. It was very interesting and inspiring to see the type of work that grad students are doing as they prepare to become the future of science.

Last year VetCell Therapeutics attended and presented a poster which introduced the concept and hypothesis for our collaborative project with Western University of Health Sciences.  The ongoing project has had some interesting results, which were discussed   at the meeting.  Our collaborator, Dr Kaur, prepared and delivered an oral presentation with abbreviated data that had been collected during the first half of the trial.  The clinical data of the project was lightly presented to give the audience an idea of the complexity of the trial and provided a taste of how things are progressing. The presentation also touched upon  the importance of working on this trial and its potential translation to human medicine.

VetCell Therapeutics also sponsored a poster created and presented by Ana Ramirez, who attends Cal Poly Pomona.  The research poster focused on a project describing biomarkers involved in atopic dermatitis patients as compared to healthy controls.  A central theme of the poster was the possibility of having a non-invasive method to diagnose atopic dermatitis. During the poster session, she received a lot of interest from the conference attendees and fielded numerous inquiries about the nature of the project.  A special congratulations must be given to Ana for placing third in the poster competition!


This is just the beginning of a lengthy path for this product usage for this indication.  So far, all has been going well for the trial. Next year is due for the trial completion and then a formal presentation of the data.  This clinical project is orchestrated with the CVM in mind and will be used as a clinical proof-of-concept and support data for the INAD.